Cyclophosphamide plus dexamethasone is an efficient initial treatment before high‐dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma
Open Access
- 31 October 2007
- Vol. 112 (1), 129-135
- https://doi.org/10.1002/cncr.23145
Abstract
BACKGROUND Today, intensive therapy that includes high‐dose melphalan with autologous stem cell transplantation (ASCT) is considered standard therapy in younger patients with newly diagnosed myeloma. When the current trial was initiated, combined vincristine, doxorubicin, and dexamethasone (VAD) was the most commonly used induction therapy before ASCT and yielded rapid major responses without interfering with stem cell harvest. However, the administration of VAD demands a central venous access, and well‐described toxicities are associated with the therapy. This randomized trial, which was initiated in 2001 by the Nordic Myeloma Study Group, was an attempt to bring a larger portion of patients to ASCT more quickly. METHODS Patients were randomized to receive either 3 cycles of VAD or 2 courses of cyclophosphamide plus dexamethasone (Cy‐Dex) (cyclophosphamide at a dose of 1000 mg/m2 on Day 1 and dexamethasone at a dose of 40 mg per day on Days 1–4 and 9–12, repeated on Day 22) as initial therapy followed by stem cell mobilization, harvest, and finally ASCT. RESULTS No significant difference was observed in the proportion of patients undergoing ASCT (VAD [86%] vs Cy‐Dex [87%]). During the first 4 months after the initiation of therapy, the mortality rates were 5.8% for VAD and 1.9% for Cy‐Dex (P = .08). The response rates after ASCT were comparable (partial response or better: VAD: 80% vs Cy‐Dex: 81%). In both groups, the median event‐free survival was 29 months, and the overall survival rate at 3 years was 75%. CONCLUSIONS The current results indicated that Cy‐Dex before ASCT has efficacy comparable to that of VAD. It also demonstrated that a short course of alkylator therapy using cyclophosphamide does not affect stem cell harvest or transplantation. Cancer 2008. © 2007 American Cancer Society.Keywords
This publication has 23 references indexed in Scilit:
- Impact of age on survival after intensive therapy for multiple myeloma: a population‐based study by the Nordic Myeloma Study GroupBritish Journal of Haematology, 2006
- Weekly Cyclophosphamide and Alternate-Day Prednisone: An Effective, Convenient, and Well-Tolerated Oral Treatment for Relapsed Multiple Myeloma After Autologous Stem Cell TransplantationMayo Clinic Proceedings, 2005
- Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myelomaBlood, 2005
- Single agent dexamethasone for pre-stem cell transplant induction therapy for multiple myelomaBone Marrow Transplantation, 2004
- Do anthracyclines have a role in the therapy of multiple myeloma?The Hematology Journal, 2000
- VAD‐based regimens as primary treatment for multiple myelomaAmerican Journal of Hematology, 1990
- INFUSION OF VINCRISTINE AND DOXORUBICIN WITH ORAL DEXAMETHASONE AS FIRST-LINE THERAPY FOR MULTIPLE MYELOMAThe Lancet, 1989
- Multiple myeloma treated with high dose intravenous melphalanBritish Journal of Haematology, 1987
- Effective Treatment of Advanced Multiple Myeloma Refractory to Alkylating AgentsThe New England Journal of Medicine, 1984
- High-dose cyclophosphamide. An effective treatment for advanced refractory multiple myelomaCancer, 1984